Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib versus enzalutamide or abiraterone in HRR-mutated metastatic castration-resistant prostate cancer
NL-OMON45674Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib, enzalutamide and abiraterone in castration-resistant prostate cancer (CRPC) and prostate cancer (PCa) (2 arms), sponsored by AstraZeneca. Primary endpoint: Radiographic progression-free survival. Started May 2017; status: active, not recruiting.
02
Drugs
olaparibenzalutamideabiraterone
03
Conditions
castration-resistant prostate cancer (CRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON45674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45674.